GlassScriptPhysician profile
Jordan Buess
NPI 1811347735
$5,337.76
in general payments reported to CMS, 2019-2025
49 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $264 · 2021: $235 · 2022: $148 · 2023: $589 · 2024: $1,899 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862 · Education: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.64 |
| Education | $829.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $685.41 | 2023-2025 | Imjudo, Imfinzi, Enhertu |
| Abbvie INC. | $524.38 | 2024-2025 | |
| Tempus Ai, INC | $399.95 | 2024-2025 | Xt Cdx |
| Lilly USA, LLC | $382.11 | 2020-2025 | Jaypirca, Retevmo, Verzenio |
| Seagen INC. | $293.12 | 2020-2025 | Tukysa |
| Astellas Pharma US INC | $221.14 | 2020-2024 | Xospata, Padcev |
| Sobi, INC | $196.91 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $196.87 | 2024-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $174.68 | 2024-2025 | Tecvayli, Balversa, Erleada |
| Incyte Corporation | $147.09 | 2022-2025 | Monjuvi |
| Galvanize Therapeutics, INC | $144.41 | 2025 | Aliya System |
| Daiichi Sankyo INC. | $137.87 | 2023-2025 | Enhertu, Vanflyta |
| Pharmacosmos Therapeutics INC. | $126.09 | 2024 | Monoferric, Cosela |
| Amgen INC. | $124.14 | 2024 | |
| Pfizer INC. | $122.07 | 2024-2025 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Buess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.